@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_head { this: np:hasAssertion dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_assertion; np:hasProvenance dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_provenance; np:hasPublicationInfo dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_publicationInfo; a np:Nanopublication . dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_assertion a np:Assertion . dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_provenance a np:Provenance . dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_publicationInfo a np:PublicationInfo . } dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_assertion { miriam-gene:1440 a ncit:C16612 . lld:C0027947 a ncit:C7057 . dgn-gda:DGN704a4e78eeb3b5119e051a5269cb78ec sio:SIO_000628 miriam-gene:1440, lld:C0027947; a sio:SIO_001120 . } dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_provenance { dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_assertion dcterms:description "[Intricate dose-response surfaces of the effects of the different treatments on colony-forming units-erythroid, reticulocytes, hematocrit, colony-forming units-granulocyte/macrophage, and absolute neutrophil count were obtained, which revealed that: (a) simultaneous EPO administration was able to maintain reticulocyte production and to protect mice from VP-16 induced anemia; (b) simultaneous G-CSF administration was able to maintain granulocyte production and to protect mice from VP-16 induced neutropenia; (c) VP-16 dose escalation was feasible when EPO or G-CSF were simultaneously administered; and (d) no increased myelotoxicity on erythroid or granuloid progenitors was observed when EPO or G-CSF was simultaneously administered with VP-16.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_curated; sio:SIO_000772 miriam-pubmed:7529132; prov:wasDerivedFrom dgn-void:ctd_human-20130708; prov:wasGeneratedBy eco:ECO_0000218 . dgn-void:ctd_human-20130708 pav:importedOn "2013-07-24"^^xsd:date . dgn-void:source_evidence_curated a eco:ECO_0000205; rdfs:comment "Gene-disease associations manually curated."@en; rdfs:label "DisGeNET evidence - CURATED"@en . } dgn-np:NP12880.RAqPLRTVp1edu6xxLfibk_AjVXAGeGlB4OBgv5pkKAmWI130_publicationInfo { this: dcterms:created "2014-10-02T12:32:04+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetrdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v2.1.0.0" . dgn-void:disgenetrdf pav:version "v2.1.0" . }